华纳药厂(688799.SH)：参股公司收到ZG-002片Ⅰ期临床研究报告

Core Viewpoint - Warner Pharmaceuticals (688799.SH) announced that its affiliate, Shanghai Zhigun Pharmaceutical Technology Co., Ltd., has completed Phase I clinical trials for ZG-002, a novel drug for autoimmune diseases, with the approval of the National Medical Products Administration [1] Group 1: Drug Development - ZG-002 is a first-class new drug developed by Zhigun Pharmaceutical, specifically targeting moderate to severe plaque psoriasis [1] - Preclinical studies indicate that ZG-002 is a potent and highly selective TYK2 allosteric inhibitor, demonstrating superior TYK2 inhibition activity and selectivity in vitro [1] - In classic animal models of psoriasis, ZG-002 has shown promising therapeutic effects, indicating its potential as a new generation of safer and more effective psoriasis treatment [1] Group 2: Safety and Efficacy - ZG-002 exhibits excellent metabolic properties and safety alongside its strong in vitro and in vivo activity [1] - The research results suggest that ZG-002 has the potential to expand its clinical applications to other autoimmune diseases [1]